Xencor (XNCR) Lifted to Hold at Zacks Investment Research

Xencor (NASDAQ:XNCR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

How to Become a New Pot Stock Millionaire

Several other equities analysts have also issued reports on the company. Cantor Fitzgerald initiated coverage on Xencor in a research report on Thursday, February 22nd. They set a “buy” rating and a $33.00 target price for the company. BidaskClub upgraded Xencor from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Wedbush boosted their target price on Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a research report on Monday, March 19th. ValuEngine upgraded Xencor from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Leerink Swann restated an “outperform” rating and set a $36.00 target price on shares of Xencor in a research report on Wednesday, March 28th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $35.17.

Shares of Xencor stock traded down $0.09 during trading on Friday, hitting $28.41. 291,263 shares of the company were exchanged, compared to its average volume of 544,687. The firm has a market capitalization of $1,547.62, a P/E ratio of -27.06 and a beta of 1.51. Xencor has a 1-year low of $18.55 and a 1-year high of $34.63.

Xencor (NASDAQ:XNCR) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. The company had revenue of $10.94 million during the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative return on equity of 16.62% and a negative net margin of 137.35%. equities research analysts expect that Xencor will post -2.09 EPS for the current fiscal year.

In related news, insider Paul A. Foster sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total value of $260,300.00. Following the completion of the transaction, the insider now directly owns 12,419 shares in the company, valued at approximately $323,266.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edgardo Baracchini, Jr. sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $29.64, for a total value of $592,800.00. Following the completion of the transaction, the insider now owns 20,000 shares of the company’s stock, valued at $592,800. The disclosure for this sale can be found here. Insiders sold a total of 105,000 shares of company stock valued at $3,101,550 over the last quarter. 4.03% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of XNCR. Redmile Group LLC boosted its position in Xencor by 12.5% during the 4th quarter. Redmile Group LLC now owns 1,350,894 shares of the biopharmaceutical company’s stock worth $29,612,000 after acquiring an additional 150,600 shares during the last quarter. Perceptive Advisors LLC boosted its position in Xencor by 1.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,313,095 shares of the biopharmaceutical company’s stock worth $28,783,000 after acquiring an additional 20,000 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its position in Xencor by 32.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 583,491 shares of the biopharmaceutical company’s stock worth $12,790,000 after acquiring an additional 144,319 shares during the last quarter. Franklin Resources Inc. boosted its position in Xencor by 3.6% during the 4th quarter. Franklin Resources Inc. now owns 538,632 shares of the biopharmaceutical company’s stock worth $11,807,000 after acquiring an additional 18,900 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Xencor by 5.9% during the 4th quarter. Geode Capital Management LLC now owns 352,526 shares of the biopharmaceutical company’s stock worth $7,727,000 after acquiring an additional 19,706 shares during the last quarter. Institutional investors and hedge funds own 79.49% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Lifted to Hold at Zacks Investment Research” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3339014/xencor-xncr-lifted-to-hold-at-zacks-investment-research.html.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Musiconomi Trading 34.7% Higher  Over Last Week
Musiconomi Trading 34.7% Higher Over Last Week
Centrality Trading Up 39.2% Over Last 7 Days
Centrality Trading Up 39.2% Over Last 7 Days
HODL Bucks  1-Day Volume Hits $5,831.00
HODL Bucks 1-Day Volume Hits $5,831.00
Zacks: Brokerages Expect ManTech International  Will Announce Quarterly Sales of $467.87 Million
Zacks: Brokerages Expect ManTech International Will Announce Quarterly Sales of $467.87 Million
Brokerages Anticipate Waddell & Reed  to Post $0.54 EPS
Brokerages Anticipate Waddell & Reed to Post $0.54 EPS
$0.14 EPS Expected for CNX Resources  This Quarter
$0.14 EPS Expected for CNX Resources This Quarter


© 2006-2018 Ticker Report. Google+.